Ring Hopes to Bring First Re-dosable Gene Therapy to the Clinic with $117M Series B

With gene therapies all the rage in modern medicine, the promising treatments face a few massive challenges including limited breadth, limitation to once-in-a-life treatment and poor tolerability. That’s why Ring Therapeutics hopes to bring in a “new era of gene therapies” to rise above the challenges of current options. A cohort of investors bought into the hope with a $117 million Series B funding round.